AUGUST 19, 2014
Protocol Closure Notice

RTOG 1122 Closure Notice
“Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma,” will close to patient accrual at 5 PM EST Tuesday, September 2, because the study has met its accrual objective.

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.